Immunogenicity of a Single Dose of Meningococcal Group C Conjugate Vaccine Given at 3 Months of Age to Healthy Infants in the United Kingdom

Abstract

In conclusion, a single priming dose of either MCC-TT or MCC-CRM197 administered at 3 months of age can be used together with the Hib/MCC-TT booster in the second year of life.

Interchangeability of meningococcal group C conjugate vaccines with different carrier proteins in the United Kingdom infant immunisation schedule

“…However, infants receiving MCC-CRM followed by MCC-TT had significantly reduced MenC and lower Hib antibody responses compared to all other groups and lower than those measured historically in similar UK trials [21]. In infants receiving mixed MCC vaccine schedules, TT-specific and DT-specific antibody responses were also influenced by which MCC vaccine was administered first.…”

Meningococcal disease in travelers

“…Off-label use of conjugate vaccines may be considered in cases when no other vaccination is available and protection against meningococcal disease is indicated (see below). Recently it has been shown that one single dose of monovalent MCC vaccination is sufficiently immunogenic in more than 95% of children at 3 months of age [62]. Further data are necessary to assess protective immunogenicity of tetravalent conjugate vaccines in the youngest age groups.…”

Is a single infant priming dose of meningococcal serogroup C conjugate vaccine in the United Kingdom sufficient?

“…Over the following months, a decline in both groups was observed followed by an increase post booster, with similar proportions in both groups. This trial did not include a control group of those vaccinated with 2 doses in infancy, however comparison of the GMTs obtained in the trial of Findlow et al 14 to those of Southern et al, 13 show that the reduction of the number of priming doses from 2 to one does not impact on the magnitude of the SBA GMT prior to boosting or that following Menitorix boosting.…”

“…These data led to the exploration of a single dose of MCC at 3 months of age, which is thought to be an immunologically less demanding age. 14 UK infants were immunised at 3 months of age with NeisVac-C Ò or Menjugate Ò along with concomitant Pediacel Ò (Sanofi Pasteur) and 7-valent pneumococcal conjugate vaccine (Prevenar, Pfizer). Results of this trial showed at one month following the priming dose (at 4 months of age) the SBA GMT was significantly higher in the group who received NeisVac-C Ò , with GMTs of 95.8 (66.4-138.2) in those vaccinated with Menjugate Ò compared to 223.3 (162.9-306.1) following NeisVac-C Ò vaccination.…”